Johann-Martin Hempel1,2, Cornelia Brendle3,4, Benjamin Bender3,4, Georg Bier3,4, Marco Skardelly5,6,4, Irina Gepfner-Tuma6,4, Franziska Eckert7,4, Ulrike Ernemann3,4, Jens Schittenhelm8,4. 1. Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany. johann-martin.hempel@uni-tuebingen.de. 2. Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany. johann-martin.hempel@uni-tuebingen.de. 3. Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany. 4. Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany. 5. Department of Neurosurgery, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany. 6. Interdisciplinary Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany. 7. Department of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany. 8. Institute of Neuropathology, Department of Pathology and Neuropathology, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.
Abstract
INTRODUCTION: To assess the predictive value of magnetic resonance imaging (MRI) gadolinium enhancement as a prognostic factor in the 2016 World Health Organization Classification of Tumors of the Central Nervous System integrated glioma groups. METHODS: Four-hundred fifty patients with histopathologically confirmed glioma were retrospectively assessed between 07/1997 and 06/2014 using gadolinium enhancement, survival, and relevant prognostic molecular data [isocitrate dehydrogenase (IDH); alpha-thalassemia/mental retardation syndrome X-linked (ATRX); chromosome 1p/19q loss of heterozygosity; and O6-methylguanine DNA methyltransferase (MGMT)]. The Kaplan-Meier method was used to assess univariate survival data. A multivariate Cox proportional hazards model was performed on significant results from the univariate analysis. RESULTS: There were significant differences in survival between patient age (p < 0.0001), WHO glioma grades (p < 0.0001), and integrated molecular profiles (p < 0.0001). Patients with IDH1/2 mutation, loss of ATRX expression, and methylated MGMT promoter showed significantly better survival than those with the IDHwild-type (p < 0.0001), retained ATRX expression (p < 0.0001), and unmethylated MGMT promoter (p = 0.019). Survival was significantly better in patients without gadolinium enhancement (p = 0.009) who were in the IDHwild-type glioma and glioma with retained ATRX expression groups (p = 0.018 and 0.030, respectively). CONCLUSIONS: In univariate analysis, the presence of gadolinium enhancement on preoperative MRI scans is an unfavorable factor for survival. Regarding the molecular subgroups, gadolinium enhancement is an unfavorable prognostic factor in gliomas with IDHwild-type and those with ATRX retention. However, in multivariate analysis only patient age, IDH1/2 mutation status, MGMT promoter methylation status, and WHO grade IV are relevant for predicting survival.
INTRODUCTION: To assess the predictive value of magnetic resonance imaging (MRI) gadolinium enhancement as a prognostic factor in the 2016 World Health Organization Classification of Tumors of the Central Nervous System integrated glioma groups. METHODS: Four-hundred fifty patients with histopathologically confirmed glioma were retrospectively assessed between 07/1997 and 06/2014 using gadolinium enhancement, survival, and relevant prognostic molecular data [isocitrate dehydrogenase (IDH); alpha-thalassemia/mental retardation syndrome X-linked (ATRX); chromosome 1p/19q loss of heterozygosity; and O6-methylguanine DNA methyltransferase (MGMT)]. The Kaplan-Meier method was used to assess univariate survival data. A multivariate Cox proportional hazards model was performed on significant results from the univariate analysis. RESULTS: There were significant differences in survival between patient age (p < 0.0001), WHO glioma grades (p < 0.0001), and integrated molecular profiles (p < 0.0001). Patients with IDH1/2 mutation, loss of ATRX expression, and methylated MGMT promoter showed significantly better survival than those with the IDHwild-type (p < 0.0001), retained ATRX expression (p < 0.0001), and unmethylated MGMT promoter (p = 0.019). Survival was significantly better in patients without gadolinium enhancement (p = 0.009) who were in the IDHwild-type glioma and glioma with retained ATRX expression groups (p = 0.018 and 0.030, respectively). CONCLUSIONS: In univariate analysis, the presence of gadolinium enhancement on preoperative MRI scans is an unfavorable factor for survival. Regarding the molecular subgroups, gadolinium enhancement is an unfavorable prognostic factor in gliomas with IDHwild-type and those with ATRX retention. However, in multivariate analysis only patient age, IDH1/2 mutation status, MGMT promoter methylation status, and WHO grade IV are relevant for predicting survival.
Authors: Martin J van den Bent; Brigitta Baumert; Sara C Erridge; Michael A Vogelbaum; Anna K Nowak; Marc Sanson; Alba Ariela Brandes; Paul M Clement; Jean Francais Baurain; Warren P Mason; Helen Wheeler; Olivier L Chinot; Sanjeev Gill; Matthew Griffin; David G Brachman; Walter Taal; Roberta Rudà; Michael Weller; Catherine McBain; Jaap Reijneveld; Roelien H Enting; Damien C Weber; Thierry Lesimple; Susan Clenton; Anja Gijtenbeek; Sarah Pascoe; Ulrich Herrlinger; Peter Hau; Frederic Dhermain; Irene van Heuvel; Roger Stupp; Ken Aldape; Robert B Jenkins; Hendrikus Jan Dubbink; Winand N M Dinjens; Pieter Wesseling; Sarah Nuyens; Vassilis Golfinopoulos; Thierry Gorlia; Wolfgang Wick; Johan M Kros Journal: Lancet Date: 2017-08-08 Impact factor: 79.321
Authors: Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling Journal: Acta Neuropathol Date: 2014-08-21 Impact factor: 17.088
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: David E Reuss; Felix Sahm; Daniel Schrimpf; Benedikt Wiestler; David Capper; Christian Koelsche; Leonille Schweizer; Andrey Korshunov; David T W Jones; Volker Hovestadt; Michel Mittelbronn; Jens Schittenhelm; Christel Herold-Mende; Andreas Unterberg; Michael Platten; Michael Weller; Wolfgang Wick; Stefan M Pfister; Andreas von Deimling Journal: Acta Neuropathol Date: 2014-11-27 Impact factor: 17.088
Authors: Adriana Olar; Khalida M Wani; Kristin D Alfaro-Munoz; Lindsey E Heathcock; Hinke F van Thuijl; Mark R Gilbert; Terri S Armstrong; Erik P Sulman; Daniel P Cahill; Elizabeth Vera-Bolanos; Ying Yuan; Jaap C Reijneveld; Bauke Ylstra; Pieter Wesseling; Kenneth D Aldape Journal: Acta Neuropathol Date: 2015-02-21 Impact factor: 17.088
Authors: Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson Journal: Radiology Date: 2008-10 Impact factor: 11.105
Authors: Niklas Thon; Sabina Eigenbrod; Eva M Grasbon-Frodl; Michael Ruiter; Jan H Mehrkens; Simone Kreth; Jörg C Tonn; Hans A Kretzschmar; Friedrich W Kreth Journal: J Neuropathol Exp Neurol Date: 2009-11 Impact factor: 3.685
Authors: David A Gutman; Lee A D Cooper; Scott N Hwang; Chad A Holder; Jingjing Gao; Tarun D Aurora; William D Dunn; Lisa Scarpace; Tom Mikkelsen; Rajan Jain; Max Wintermark; Manal Jilwan; Prashant Raghavan; Erich Huang; Robert J Clifford; Pattanasak Mongkolwat; Vladimir Kleper; John Freymann; Justin Kirby; Pascal O Zinn; Carlos S Moreno; Carl Jaffe; Rivka Colen; Daniel L Rubin; Joel Saltz; Adam Flanders; Daniel J Brat Journal: Radiology Date: 2013-02-07 Impact factor: 11.105
Authors: Ilanah J Pruis; Stephan R Koene; Sebastian R van der Voort; Fatih Incekara; Arnaud J P E Vincent; Martin J van den Bent; Geert J Lycklama À Nijeholt; Rishi D S Nandoe Tewarie; Sophie E M Veldhuijzen van Zanten; Marion Smits Journal: Neurooncol Adv Date: 2022-02-21